Dr. Chen serves on the Apollomics Board as an independent director since March 2023. Dr. Chen has extensive experiences in therapeutics research and development, regulatory strategy, and company operation. He was the CEO and Chairman of Maxpro Capital Acquisition Corp. which merged with Apollomics in March 2023. Currently he is a managing partner at Maxpro ventures. Prior to joining Maxpro ventures, Dr. Chen held management and R&D positions at various biotech companies including SyneuRx International Inc., Meridigen, Celgene, Amcyte, and VivoRx.

Dr. Chen received his Ph.D. in Microbiology and Molecular Genetics from Rutgers, The State University of New Jersey and The University of Medicine and Dentistry of New Jersey. He did his postdoctoral training in neuroscience at Caltech.